| 1 |
Zhang X, Li B, Lu Z, Hu M, Zhao G, Xu S, Wu Z, Chu T, Qi F, Wu S, Nie G, Li S, Liu R. Nanoparticle-based combination of LMWH and doxorubicin for the efficient treatment of hepatocellular carcinoma with portal vein tumor thrombus. Nano Today 2023;49:101787. [DOI: 10.1016/j.nantod.2023.101787] [Reference Citation Analysis]
|
| 2 |
Kong SY, Song JJ, Jin YQ, Deng MJ, Yan JX. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Acta Clin Belg 2023;78:171-9. [PMID: 35587164 DOI: 10.1080/17843286.2022.2076791] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Chen Y, Hong H, Fang W, Zhang X, Luo H, Chen Z, Yu J, Fan W, Chi X, Peng Y. Toripalimab in combination with Anlotinib for unresectable hepatocellular carcinoma after SBRT: A prospective, single-arm, single-center clinical study. Front Oncol 2023;13. [DOI: 10.3389/fonc.2023.1113389] [Reference Citation Analysis]
|
| 4 |
Farasati Far B, Rabie D, Hemati P, Fooladpanjeh P, Faal Hamedanchi N, Broomand Lomer N, Karimi Rouzbahani A, Naimi-jamal MR. Unresectable Hepatocellular Carcinoma: A Review of New Advances with Focus on Targeted Therapy and Immunotherapy. Livers 2023;3:121-160. [DOI: 10.3390/livers3010011] [Reference Citation Analysis]
|
| 5 |
Fu Y, Peng W, Zhang W, Yang Z, Hu Z, Pang Y, Hu D, Chen J, Wang J, Zhou Z, Xu L, Chen M, Zhang Y. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis. J Gastroenterol 2023. [PMID: 36894804 DOI: 10.1007/s00535-023-01976-x] [Reference Citation Analysis]
|
| 6 |
Li JX, Zhang RJ, Qiu MQ, Yan LY, He ML, Long MY, Zhong JH, Lu HY, Zhou HM, Xiang BD, Liang SX. Non-classic radiation-induced liver disease after intensity-modulated radiotherapy for Child-Pugh grade B patients with locally advanced hepatocellular carcinoma. Radiat Oncol 2023;18:48. [PMID: 36890592 DOI: 10.1186/s13014-023-02232-5] [Reference Citation Analysis]
|
| 7 |
Wang XH, Liu CJ, Wen HQ, Duan XH, Jiao YQ, Liu YJ, Chen MS, Zhu KS, Mao XH, Zhou QF. Effectiveness of lenvatinib plus immune checkpoint inhibitors in primary advanced hepatocellular carcinoma beyond oligometastasis. Clin Transl Med 2023;13:e1214. [PMID: 36855781 DOI: 10.1002/ctm2.1214] [Reference Citation Analysis]
|
| 8 |
Guo C, Zhang J, Huang X, Chen Y, Sheng J, Huang X, Sun J, Xiao W, Sun K, Gao S, Que R, Shen Y, Zhang M, Wu J, Bai X, Liang T. Preoperative sintilimab plus transarterial chemoembolization for hepatocellular carcinoma exceeding the Milan criteria: A phase II trial. Hepatol Commun 2023;7:e0054. [PMID: 36757445 DOI: 10.1097/HC9.0000000000000054] [Reference Citation Analysis]
|
| 9 |
Xu Q, Zeng J, Zeng J, Huang Y, Guo P, Lan L. The effect of Microvascular Invasion on Hepatocellular Carcinoma with Portal Vein Tumor Thrombus after Hepatectomy: A multicenter study.. [DOI: 10.21203/rs.3.rs-2523854/v1] [Reference Citation Analysis]
|
| 10 |
Zhou XH, Li JR, Zheng TH, Chen H, Cai C, Ye SL, Gao B, Xue TC. Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy. Clin Exp Metastasis 2023;40:5-32. [PMID: 36318440 DOI: 10.1007/s10585-022-10188-1] [Reference Citation Analysis]
|
| 11 |
Ji X, Xu Z, Sun J, Li W, Duan X, Wang Q. Lenvatinib with or without Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: a retrospective study.. [DOI: 10.21203/rs.3.rs-2452311/v1] [Reference Citation Analysis]
|
| 12 |
Guo WX, Yang SY, Guo L, Feng JK, Xue J, Shi J, Lau WY, Yu D, Cheng SQ. A new and rare type of hepatocellular carcinoma: Survival and gene analysis of portal vein tumour thrombus-type hepatocellular carcinoma. Pathol Res Pract 2023;241:154260. [PMID: 36509007 DOI: 10.1016/j.prp.2022.154260] [Reference Citation Analysis]
|
| 13 |
Wang K, Xiang YJ, Yu HM, Cheng YQ, Liu ZH, Zhong JY, Feng S, Ni QZ, Zhu HF, Pan WW, Li JJ, Liang C, Zhou HK, Meng Y, Lau WY, Cheng SQ. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study. Front Immunol 2023;14:1107542. [PMID: 36875125 DOI: 10.3389/fimmu.2023.1107542] [Reference Citation Analysis]
|
| 14 |
Kang Wang, Hong-Ming Yu, Yan-Jun Xiang, Yu-Qiang Cheng, Qian-Zhi Ni, Wei-Xing Guo, Jie Shi, Shuang Feng, Jian Zhai, Shu-Qun Cheng. Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol. BMJ Open 2022;12:e064688. [PMID: 36521893 DOI: 10.1136/bmjopen-2022-064688] [Reference Citation Analysis]
|
| 15 |
Jearth V, Patil PS, Mehta S, Goel M, Patkar S, Kulkarni S, Shetty N, Ostwal V, Ramaswamy A, Sastri S, Engineer R. A study of the clinical profile, predictors, prognostic features, and survival of patients with hepatocellular carcinoma having macroscopic portal vein tumor thrombosis. Indian J Gastroenterol 2022;41:533-43. [PMID: 36715840 DOI: 10.1007/s12664-022-01289-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 16 |
Ji M, Zou H, Shu B, Liu G, Zhang B, Xu Z, Pang F, Cheng M, Sun Y, Du T, Sun C, Zhu C. Prognostic analysis of hepatocellular carcinoma with macrovascular invasion after liver resection and a successful case of conversion therapy. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.1042431] [Reference Citation Analysis]
|
| 17 |
Yan J, Deng M, Kong S, Li T, Lei Z, Zhang L, Zhuang Y, He X, Wang H, Fan H, Guo Y. Transarterial chemoembolization in combination with programmed death-1/programmed cell death-ligand 1 immunotherapy for hepatocellular carcinoma: A mini review. iLIVER 2022. [DOI: 10.1016/j.iliver.2022.10.001] [Reference Citation Analysis]
|
| 18 |
Sha M, Chen C, Shen C, Jeong S, Sun H, Xu N, Hang H, Cao J, Tong Y. Clinical analysis of deceased donor liver transplantation in the treatment of hepatocellular carcinoma with segmental portal vein tumor thrombus: A long-term real-world study. Front Oncol 2022;12:971532. [DOI: 10.3389/fonc.2022.971532] [Reference Citation Analysis]
|
| 19 |
Jin Z, Wu G, Xu B, Wang J, Zhu H, Guo Y, Peng M, Peng T, Wen Z. Case Report: Combining liver partition and portal vein ligation after thrombectomy for tumor isolation (CLAPT) to treat advanced hepatocellular carcinoma with portal vein tumor thrombosis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.928452] [Reference Citation Analysis]
|
| 20 |
Huang W, Gong J, Wang Q, Wang Z, Liu Q, Liu J, Gu J, Ding X, Wu Z. Evaluation of D-TACE combined with endovascular brachytherapy for HCC with MPVTT. Front Oncol 2022;12:973357. [DOI: 10.3389/fonc.2022.973357] [Reference Citation Analysis]
|
| 21 |
Shi Y, Shang J, Li Y, Zhong D, Zhang Z, Yang Q, Lai C, Feng T, Yao Y, Huang X. ITGA5 and ITGB1 contribute to Sorafenib resistance by promoting vasculogenic mimicry formation in hepatocellular carcinoma. Cancer Med 2023;12:3786-96. [PMID: 35946175 DOI: 10.1002/cam4.5110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 22 |
Zhang CH, Cheng Y, Zhang S, Fan J, Gao Q. Changing epidemiology of hepatocellular carcinoma in Asia. Liver Int 2022;42:2029-41. [PMID: 35319165 DOI: 10.1111/liv.15251] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
|
| 23 |
Zhao Z, Zheng Z, Huang J, Wang J, Peng T, Lin Y, Jian Z. Expression of ALG3 in Hepatocellular Carcinoma and Its Clinical Implication. Front Mol Biosci 2022;9:816102. [DOI: 10.3389/fmolb.2022.816102] [Reference Citation Analysis]
|
| 24 |
Liu DM, Leung TW, Chow PK, Ng DC, Lee RC, Kim YH, Mao Y, Cheng YF, Teng GJ, Lau WY. Clinical consensus statement: Selective internal radiation therapy with yttrium 90 resin microspheres for hepatocellular carcinoma in Asia. Int J Surg 2022;102:106094. [PMID: 35662438 DOI: 10.1016/j.ijsu.2021.106094] [Reference Citation Analysis]
|
| 25 |
Qiu H, Ke S, Cai G, Wu Y, Wang J, Shi W, Chen J, Peng J, Yu B, Chen Y. An exploratory clinical trial of apatinib combined with intensity-modulated radiation therapy for patients with unresectable hepatocellular carcinoma. Cancer Med 2023;12:213-22. [PMID: 35633045 DOI: 10.1002/cam4.4900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 26 |
Lin X, Xiao M, Gu YJ, Zhu HK, Li MX, Zhuang L, Zheng SS, Li QY. The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00120-5. [PMID: 35568681 DOI: 10.1016/j.hbpd.2022.05.002] [Reference Citation Analysis]
|
| 27 |
Srivastava A, Parambath HK, Ramdulari AV, Saxena H, Kumar R, Pandey S, Shalimar, Gupta S, Jee B. Is hepatocellular carcinoma complicated with portal vein tumor thrombosis potentially curable by radiotherapy in the form of stereotactic body radiation therapy? Int J Radiat Biol 2022;:1-15. [PMID: 35311612 DOI: 10.1080/09553002.2022.2055800] [Reference Citation Analysis]
|
| 28 |
Lyu T, Yao H, Wang J, Song L, Tong X, Zou Y. Treatment response, survival and safety profile of transarterial chemoembolization using different sizes of drug-eluting beads in hepatocellular carcinoma patients with portal vein tumor thrombus. Clin Res Hepatol Gastroenterol 2022;46:101819. [PMID: 34619365 DOI: 10.1016/j.clinre.2021.101819] [Reference Citation Analysis]
|
| 29 |
Lee CH, Chen AH, Hung SP, Hsieh CE, Tseng JH, Chen PJ, Cheng JY, Chang JT, Chan KM, Lin SM, Lin CC, Chen WT, Chen WY, Huang BS. Proton Beam Therapy in Managing Unresectable Hepatocellular Carcinoma with Bile Duct Invasion. Cancers (Basel) 2022;14:1616. [PMID: 35406392 DOI: 10.3390/cancers14071616] [Reference Citation Analysis]
|
| 30 |
Choe JW, Lee HY, Rim CH. Will the collaboration of surgery and external radiotherapy open new avenues for hepatocellular carcinoma with portal vein thrombosis? World J Gastroenterol 2022; 28(7): 704-714 [DOI: 10.3748/wjg.v28.i7.704] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 31 |
Anton A, Campreciós G, Pérez-Campuzano V, Orts L, García-Pagán JC, Hernández-Gea V. The Pathophysiology of Portal Vein Thrombosis in Cirrhosis: Getting Deeper into Virchow's Triad. J Clin Med 2022;11:800. [PMID: 35160251 DOI: 10.3390/jcm11030800] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
|
| 32 |
Galun D, Mijac D, Filipovic A, Bogdanovic A, Zivanovic M, Masulovic D. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective. JPM 2022;12:149. [DOI: 10.3390/jpm12020149] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
|
| 33 |
Cheng S, Yu X, Liu S, Jin Z, Xue H, Wang Z, Xie P. Development of a Prognostic Nomogram in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus Following Trans-Arterial Chemoembolization with Drug-Eluting Beads. Cancer Manag Res 2021;13:9367-77. [PMID: 34992462 DOI: 10.2147/CMAR.S341672] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 34 |
周 雍. Progress in Transformation Therapy of Hepatocellular Carcinoma with Portal Vein Cancer Thrombus. ACM 2022;12:11521-11527. [DOI: 10.12677/acm.2022.12121661] [Reference Citation Analysis]
|
| 35 |
Fu S, Lai H, Huang M, Li Q, Liu Y, Zhang J, Huang J, Chen X, Duan C, Li X, Wang T, He X, Yan J, Lu L. Multi-task deep learning network to predict future macrovascular invasion in hepatocellular carcinoma. EClinicalMedicine 2021;42:101201. [PMID: 34917908 DOI: 10.1016/j.eclinm.2021.101201] [Cited by in Crossref: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 36 |
Aramaki O, Takayama T, Moriguchi M, Sakamoto H, Yodono H, Kokudo N, Yamanaka N, Kawasaki S, Sasaki Y, Kubota K, Otsuji E, Tanaka S, Matsuyama Y, Fujii M; ACE 500 study group. Arterial chemoembolisation with cisplatin versus epirubicin for hepatocellular carcinoma (ACE 500 study): A multicentre, randomised controlled phase 2/3 trial. Eur J Cancer 2021;157:373-82. [PMID: 34563992 DOI: 10.1016/j.ejca.2021.08.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 37 |
Zhou W, Fang DL, He Y. Screening potential prognostic biomarkers for portal vein emboli in patients with hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1927-38. [PMID: 34532139 DOI: 10.21037/jgo-21-433] [Reference Citation Analysis]
|
| 38 |
Su TS, Li LQ, Liang SX, Xiang BD, Li JX, Ye JZ, Li LQ. A Prospective Study of Liver Regeneration After Radiotherapy Based on a New (Su'S) Target Area Delineation. Front Oncol 2021;11:680303. [PMID: 34513671 DOI: 10.3389/fonc.2021.680303] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 39 |
Zheng X, Wang P, Li L, Yu J, Yu C, Xu L, Li L, Dai F, Feng L, Zou H, Chen X, Zhang M, Xu M. Cancer-Associated Fibroblasts Promote Vascular Invasion of Hepatocellular Carcinoma via Downregulating Decorin-integrin β1 Signaling. Front Cell Dev Biol 2021;9:678670. [PMID: 34504839 DOI: 10.3389/fcell.2021.678670] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 40 |
Lee SJ, Kim M, Kwak YK, Kang HJ. MRI-guided radiotherapy for PVTT in HCC patients: evaluation of the efficacy and safety. J Cancer Res Clin Oncol 2021. [PMID: 34490584 DOI: 10.1007/s00432-021-03788-z] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 41 |
Zhang XP, Zhao GD, Liu Q, Liu R. Letter to the Editor: Recognizing Significant Role of Neoadjuvant Radiotherapy for HCC With Vascular Invasion. Hepatology 2021;74:1719. [PMID: 33666266 DOI: 10.1002/hep.31785] [Reference Citation Analysis]
|
| 42 |
Cao Y, Sun T, Guo X, Ouyang T, Kan X, Chen L, Liang B, Wang M, Zheng C. Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study. Front Oncol 2021;11:673378. [PMID: 34414104 DOI: 10.3389/fonc.2021.673378] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 43 |
Ma Z, Li Z, Wang S, Zhou Q, Ma Z, Liu C, Huang B, Zheng Z, Yang L, Zou Y, Zhang C, Huang S, Hou B. SLC39A10 Upregulation Predicts Poor Prognosis, Promotes Proliferation and Migration, and Correlates with Immune Infiltration in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:899-912. [PMID: 34395329 DOI: 10.2147/JHC.S320326] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 44 |
Liu BJ, Gao S, Zhu X, Guo JH, Kou FX, Liu SX, Zhang X, Wang XD, Cao G, Chen H, Liu P, Zhu LZ, Xu HF, Yang RJ. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis. Biomed Res Int 2021;2021:6670367. [PMID: 34337041 DOI: 10.1155/2021/6670367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 45 |
Li X, Ye Z, Lin S, Pang H. Predictive factors for survival following stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumour thrombosis and construction of a nomogram. BMC Cancer 2021;21:701. [PMID: 34126955 DOI: 10.1186/s12885-021-08469-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 46 |
Li B, Lam KO, Lee VH, Fang W. Editorial: Immunotherapy in Hepatocellular Carcinoma. Front Oncol 2021;11:698515. [PMID: 34178698 DOI: 10.3389/fonc.2021.698515] [Reference Citation Analysis]
|
| 47 |
Jin ZC, Chen L, Zhong BY, Zhu HD, Zeng CH, Li R, Guo JH, He SC, Deng G, Zhu XL, Ni CF, Teng GJ. Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:602700. [PMID: 34026598 DOI: 10.3389/fonc.2021.602700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 48 |
Lin T, Lin Z, Mai P, Zhang E, Peng L. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. Aging (Albany NY) 2021;13:11786-807. [PMID: 33878734 DOI: 10.18632/aging.202876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 49 |
Chen KL, Gao J. Factors influencing the short-term and long-term survival of hepatocellular carcinoma patients with portal vein tumor thrombosis who underwent chemoembolization. World J Gastroenterol 2021; 27(13): 1330-1340 [PMID: 33833486 DOI: 10.3748/wjg.v27.i13.1330] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 50 |
Chu Z, Shi X, Chen G, He X, Qian Y, Wang H, Tao L, Liu Y, Jiang W, Chen J. COE Inhibits Vasculogenic Mimicry by Targeting EphA2 in Hepatocellular Carcinoma, a Research Based on Proteomics Analysis. Front Pharmacol 2021;12:619732. [PMID: 33867982 DOI: 10.3389/fphar.2021.619732] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 51 |
Ding J, Li HY, Zhang L, Zhou Y, Wu J. Hedgehog Signaling, a Critical Pathway Governing the Development and Progression of Hepatocellular Carcinoma. Cells 2021;10:123. [PMID: 33440657 DOI: 10.3390/cells10010123] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 52 |
Levi Sandri GB. Management of Portal Vein Thrombosis in Liver Cancer. Portal Vein Thrombosis 2021. [DOI: 10.1007/978-981-33-6538-4_11] [Reference Citation Analysis]
|
| 53 |
Vitale A, Trevisani F, Farinati F, Cillo U. Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy. Hepatology 2020;72:2206-18. [PMID: 32064645 DOI: 10.1002/hep.31187] [Cited by in Crossref: 68] [Cited by in F6Publishing: 76] [Article Influence: 22.7] [Reference Citation Analysis]
|
| 54 |
Yang X, Zhu Y, Zhao X, Li JH, Xu D, Jia HL, Zhang JB. The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection. Cancer Manag Res 2020;12:12077-86. [PMID: 33262656 DOI: 10.2147/CMAR.S278777] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 55 |
Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020;12:738-53. [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 56 |
Zhang L, Sun JH, Hou ZH, Zhong BY, Yang MJ, Zhou GH, Wang WS, Huang P, Zhang S, Li Z, Zhu XL, Yan ZP, Ni CF. Prognosis Nomogram for Hepatocellular Carcinoma Patients with Portal Vein Invasion Undergoing Transarterial Chemoembolization Plus Sorafenib Treatment: A Retrospective Multicentre Study. Cardiovasc Intervent Radiol 2021;44:63-72. [PMID: 32965582 DOI: 10.1007/s00270-020-02579-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 57 |
Hu Y, Qin T, Li S, Zhang T, Xue J. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial. Front Oncol. 2020;10:1589. [PMID: 32984021 DOI: 10.3389/fonc.2020.01589] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
|
| 58 |
Liu BJ, Gao S, Zhu X, Guo JH, Zhang X, Chen H, Wang XD, Yang RJ. Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma. World J Gastrointest Oncol 2020; 12(6): 663-676 [PMID: 32699581 DOI: 10.4251/wjgo.v12.i6.663] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 59 |
Yang Z, Luo FZ, Wang S, Lerut J, Zhuang L, Li QY, Xu X, Zheng SS. Alpha-fetoprotein and (18)F-FDG standard uptake value predict tumor recurrence after liver transplantation for hepatocellular carcinoma with portal vein tumor thrombosis: Preliminary experience. Hepatobiliary Pancreat Dis Int 2020;19:229-34. [PMID: 32303439 DOI: 10.1016/j.hbpd.2020.03.009] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 60 |
Li S, Li L, Li B, Wang W. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis. Br J Radiol 2020;93:20190279. [PMID: 32464068 DOI: 10.1259/bjr.20190279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 61 |
Huang S, Zhang C, Sun C, Hou Y, Zhang Y, Tam NL, Wang Z, Yu J, Huang B, Zhuang H, Zhou Z, Ma Z, Sun Z, He X, Zhou Q, Hou B, Wu L. Obg-like ATPase 1 (OLA1) overexpression predicts poor prognosis and promotes tumor progression by regulating P21/CDK2 in hepatocellular carcinoma. Aging (Albany NY) 2020;12:3025-41. [PMID: 32045367 DOI: 10.18632/aging.102797] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 62 |
Ibrahim C, Parra N, Macedo FI, Yakoub D. Is hepatic resection better than transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis? J Gastrointest Oncol 2019;10:1064-72. [PMID: 31949923 DOI: 10.21037/jgo.2019.09.07] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
